Trial · NCT01478256
Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
NCT01478256, Phase 4, Completed, John, George, M.D.; results first posted 2013-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis. Trials, record NCT01478256. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01478256
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
- NCT number
- NCT01478256
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 30 participants, actual
- Lead sponsor
- John, George, M.D.
- Conditions
- Blepharitis
- Interventions
- Erythromycin, Besifloxocin
- First posted
- 2011-11-23
- Last updated
- 2013-12-19
- Results first posted
- 2013-11-20
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in Signs and Symptoms of Blepharitis | Four weeks | Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics |
| Secondary | Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics | Three weeks | Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement in Signs and Symptoms of Blepharitis | Four weeks | participants | NUMBER | |
| SECONDARY | Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics | Three weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improvement in Signs and Symptoms of Blepharitis | Besifloxocin | 15 | participants | ||
| Improvement in Signs and Symptoms of Blepharitis | Erythromycin | 15 | participants | ||
| Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics | Besifloxocin | 15 | participants | ||
| Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics | Erythromycin | 15 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Besifloxocin | 15 | |
| Overall Study | STARTED | Erythromycin | 15 | |
| Overall Study | COMPLETED | Besifloxocin | 15 | |
| Overall Study | COMPLETED | Erythromycin | 15 | |
| Overall Study | NOT COMPLETED | Besifloxocin | 0 | |
| Overall Study | NOT COMPLETED | Erythromycin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Besifloxocin | ||
| Total, all-cause mortality | Erythromycin | ||
| Total, other adverse events | Besifloxocin | 0 | 15 |
| Total, other adverse events | Erythromycin | 0 | 15 |
| Total, serious adverse events | Besifloxocin | 0 | 15 |
| Total, serious adverse events | Erythromycin | 0 | 15 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Besifloxocin vs Erythromycin: Improvement in Signs and Symptoms of Blepharitis | Trial comparisons |
| Besifloxocin vs Erythromycin: Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics | Trial comparisons |
| Besifloxocin vs Erythromycin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01478256
GET https://conductscience.org/api/trials/v1/NCT01478256/registered